Biotechnology - Cell Therapeutics, Regulation

Filter

Popular Filters

Cell Thera’s NHL drug Pixuvri gets backing from UK’s NICE

27-02-2014

US biotech firm Cell Therapeutics has received positive news from the UK’s drugs watchdog for use of…

BiotechnologyCell TherapeuticsNorthern EuropeOncologyPixuvriPricingRegulationUK

FDA lifts partial clinical hold on Cell Therapeutics’ tosedostat

FDA lifts partial clinical hold on Cell Therapeutics’ tosedostat

02-01-2014

US biotech firm Cell Therapeutics has received notification from the US Food and Drug Administration…

BiotechnologyCell TherapeuticsNorth AmericaOncologyRegulationtosedostatUSA

UK’s NICE says yes to Cell Thera’s non-Hodgkin’s lymphoma drug Pixuvri

UK’s NICE says yes to Cell Thera’s non-Hodgkin’s lymphoma drug Pixuvri

31-12-2013

US biotech firm Cell Therapeutics’ Pixuvri (pixantrone), a treatment for an aggressive type of cancer…

BiotechnologyCell TherapeuticsEuropeOncologyPixuvriPricingRegulation

US FDA puts partial clinical hold on Cell Thera's blood cancer drug tosedostat trial

25-06-2013

US biotech firm Cell Therapeutics (Nasdaq: CTIC) revealed this week in a filing with the Securities Exchange…

BiotechnologyCell TherapeuticsNorth AmericaOncologyRegulationResearchtosedostat

Germany's G-BA issues final assessment for Cell Thera's Pixuvri

21-05-2013

USA-based Cell Therapeutics (Nasdaq: CTIC) says that Germany's Federal Joint Committee (G-BA) has issued…

BiotechnologyCell TherapeuticsEuropeOncologyPharmaceuticalPixuvriPricingRegulation

Positive NICE recommendation for Novartis' Lucentis, but not for Cell Thera's Pixuvri

11-04-2013

There was good news for Swiss drug major Novartis (NOVN: VX) this morning, when UK drugs watchdog the…

BiotechnologyCell TherapeuticsEuropeLucentisNovartisOncologyOphthalmicsPharmaceuticalPixuvriPricingRegulation

Germany's IQWiG finds no added benefit for Komboglyze or for Pixuvri

04-03-2013

In an early benefit assessment under Germany's Act on the Reform of the Market for Medicinal Products…

AstraZenecaBiotechnologyBristol-Myers SquibbCell TherapeuticsDiabetesEuropeKomboglyzemetforminOncologyPharmaceuticalPixuvriPricingRegulationsaxagliptin

Cell Therapeutics' Pixuvri cleared in EU for NHL

14-05-2012

US biotech firm Cell Therapeutics (Nasdaq and MTA: CTIC) last week received conditional marketing authorization…

BiotechnologyCell TherapeuticsEuropeOncologyPharmaceuticalPixuvriRegulation

EMA turns positive on orlistat and aprotinin; CHMP backs Pixuvri

20-02-2012

Finalizing its review on orlistat-containing medicines and the possible risk of severe liver injuries,…

AlliBayerBiotechnologyCardio-vascularCell TherapeuticsEuropeGlaxoSmithKlineMetabolicsOncologyorlistatPharmaceuticalPixuvriRegulationRocheTrasylolXenical

Cell Therapeutics updates on Pixuvri

30-01-2012

Seattle, USA-based Cell Therapeutics (Nasdaq and MTA: CTIC) says that it has voluntarily withdrawn its…

BiotechnologyCell TherapeuticsNorth AmericaOncologyPixuvriRegulation

Back to top